DYNE Therapeutics is a clinical-stage biopharmaceutical company developing therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform, which delivers therapeutic payloads to muscle tissue and the central nervous system by leveraging transferrin receptor 1 (TfR1). The platform consists of a proprietary Fab antibody engineered to target muscle cells with low immunogenicity, a linker enabling precise intracellular release, and optimized payloads including antisense oligonucleotides, morpholino oligomers, and enzymes selected to address specific genetic mutations. The company is advancing multiple programs across large rare disease markets—including Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy, and Pompe disease—and plans to generate revenue through global commercialization of approved products via a targeted sales force, with patent protection covering the platform through the mid-2040s.